[1]
|
P. Cohen, “Protein Kinases the Major Drug Targets of the Twenty First Century?” Nature Reviews Drug Discovery, Vol. 1, No. 4, 2002, pp. 309-315.
doi:10.1038/nrd773
|
[2]
|
M. Krug and A. Hilgeroth, “Recent Advances in the Development of Multi Kinase Inhibitors,” Mini-Reviews in Medicinal Chemistry, Vol. 8, No. 13, 2008, pp. 1312-1327. doi:10.2174/138955708786369591
|
[3]
|
T. L. Underiner, B. Ruggeri and D. E. Gingrich, “Development of Vascu-lar Endothelial Growth Factor Receptor (VEGFR) Kinase Inhibitors as Anti-Angiogenic Agents in Cancer Therapy,” Current Medicinal Chemistry, Vol. 11, No. 6, 2004, pp. 731-745.
doi:10.2174/0929867043455756
|
[4]
|
L. Q. Chow and S. Gail Eckhardt, “Sunitinib: From Rational Design to Clinical Efficacy,” Journal of Clinical Oncology, Vol. 25, No. 19, 2007, p. 2858.
doi:10.1200/JCO.2006.06.3602
|
[5]
|
F. Sandrine, D. George, S. William and R. Eric, “Molecular Basis for Sunitinib Efficacy and Future Clinical Development,” Nature Reviews Drug Discovery, Vol. 6, No. 9, 2007, pp. 734-745. doi:10.1038/nrd2380
|
[6]
|
A. L. Cheryl, B. M. Phyllis, L. W. F. Stacey, F. B. Joseph, W. R. Anthony, M. P. Rosenberg, C. J. Henry, K. L. Mitchener, M. K. Klein, J. G. Hintermeister, P. J. Bergman, G. C. Couto, G. N. Mauldin and G. M. Michels, “Multi-Center, Placebo-Controlled, Double-Blind, Randomized Study of Oral Toceranib Phosphate (su11654), a Receptor Tyro-sine Kinase Inhibitor, for the Treatment of Dogs with Recurrent (either Local or Distant) Mast Cell Tumor Following Surgical Excision,” Clinical Cancer Research, Vol. 15, No.
|
[7]
|
D. M. McLean, “Methisazone Therapy in Vaccinia Complications,” Annals of the New York Academy of Sciences, Vol. 284, 1977, pp. 118-121.
doi:10.1111/j.1749-6632.1977.tb21942.x
|
[8]
|
A. O. Donnell, A. Padhani, C. Hayes, A. J. Kakkar, M. Leach, J. M. Trigo, M. Scurr, F. Raynaud, S. Phillips, W. Aherne, A. Hardcastle, P. Workman, A. Hannah and I. Judson, “A Phase I Study of the Angiogenesis Inhibitor SU5416 (Semaxanib) in Solid Tumors, Incorporating Dynamic Contrast MR Pharmacodynamic End Points,” British Journal of Cancer, Vol. 93, No. 8, 2005, pp. 876-883. doi:10.1038/sj.bjc.6602797
|
[9]
|
G. F. Matthew, Z. Andrew, W. Richard, V. Ennapadam, L. Eric, H. Lucy, A. Timothy, G. William, F. Martin and G. P. David, “A Phase II Study of SU5416 in Patients with Advanced or Recurrent Head and Neck Cancers,” Invest New Drugs, Vol. 25, 2007, pp. 162-172.
|
[10]
|
S. Karsten, F. Florian, V. Robert and H. Wolfgang, “The Protein Tyrosine Kinase Inhibitor SU5614 Inhibits VEGF-Induced Endothelial Cell Sprouting and Induces Growth Arrest and Apoptosis by Inhibition of c-kit in AML Cells,” Experimental Hematology, Vol. 30, No. 7, 2002, pp. 767-773. doi:10.1016/S0301-472X(02)00837-8
|
[11]
|
S. Cristiana, V. Lucia, G. Giacomo, T. Jose, M. Irene, L. Anna, B. Alberta, I. Nicoletta, M. Silvia and G. Luca, “Phase I Clinical and Pharmacological Evaluation of the Multi Tyrosine Kinase Inhibitor SU006668 by Chronic Oral Dosing,” European Journal of Cancer, Vol. 42, No. 2, 2006, pp. 171-178. doi:10.1016/j.ejca.2005.09.033
|
[12]
|
A. D. Laird, P. Vajkoczy, L. K. Shawver, A. Thurnher, C. Liang, M. Mohammadi, J. Schles Singer, A. Ullrich, S. R. Hub-bard, R. A. Blake, T. A. Fong, L. M. Strawn, L. Sun, C. Tang, R. Hawtin, F. Tang, N. Shenoy, K. P. Hirth, G. McMahon and J. M. Cherrington, “SU6668 Is a Potent Antiangiogenic and Antitumor Agent That Induces Regression of Established Tumor,” Cancer Research, Vol. 60, 2000, pp. 4152-4160.
|
[13]
|
W. Fiedler, G. Giaccone, P. Lasch, I. V. Horst, N. Brega, R. Courtney, A. Abbat-tista, D. R. Shalinsky, C. Bokemeyer and E. Boven, “Phase I Trial of SU14813 in Patients with Advanced Solid Malignancies,” Annals of Oncology, Vol. 22, No. 1, 2011, pp. 195-201.
doi:10.1093/annonc/mdq313
|
[14]
|
P. Shem, A. D. Laird and D. B. Mendel, “SU14813: A Novel Multiple Receptor Tyrosine Kinase Inhibitor with Potent Antiangiogenic and Antitumor Activity,” Molecular Cancer Therapeutics, Vol. 5, No. 7, 2006, pp. 1774-1782. doi:10.1158/1535-7163.MCT-05-0333
|
[15]
|
Z. Yitzhak, V. V. Angelina, M. Michaela, S. Bruno, B. L. Wieslawa, H. G. Richard, S. Nikolaus and M. A. Daniel, “Differential Inhibition Sensitivities of MET Mutants to the Small Molecule Inhibitor SU11274,” Cancer Letters, Vol. 289, No. 2, 2010, pp. 228-236.
doi:10.1016/j.canlet.2009.08.017
|
[16]
|
W. Xueyan, L. Phuong and L. Congxin, “Potent and Selective Inhibitors of the Met [Hepatocyte Growth Factor/Scatter Factor (HGF/SF) Receptor] Tyrosine Kinase Block HGF/ SF-Induced Tumor Cell Growth and Invasion,” Molecular Cancer Therapeutics, Vol. 2, No. 11, 2003, pp. 1085-1092.
|
[17]
|
E. H. Brett, L. B. Carlo and K. Dong-woo, “A Population Pharmacokinetic Meta-Analysis of Sunitinib Malate (SU11248) and Its Primary Metabolite (SU12662) in Healthy Volunteers and Oncology Pa-tients,” Clinical Cancer Research, Vol. 15, No. 7, 2009, pp. 2497-2506.
doi:10.1158/1078-0432.CCR-08-1893
|
[18]
|
E K. Grand, A. J. Chase, C. Heath, A. Rahemtulla and N. C. P. Cross, “Targeting FGFR3 in Multiple Myeloma: Inhibition of t(4;14)-Positive Cells by SU5402 and PD173074,” Leu-kemia, Vol. 18, No. 5, 2004, pp. 962-966.
doi:10.1038/sj.leu.2403347
|
[19]
|
P. Neela, S. Li, M. Deborah, C. Hui, M. L. Kathleen, L. Phuong, G. M. Katherine, W. Xueyan, R. Audie, T. Danny, A. D. Laird, X. M. Yu, Z. Qingling, T. Cho, M. M. Gerald and H. An-thony, “A Selective and Oral Small Molecule Inhibitor of VEGFR-2 and VEGFR-1 Inhibits Neovascularization and Vascular Permeability,” Journal of Pharmacology and Experimental Therapeutics, Vol. 306, No. 3, 2003, pp. 838-845.
|
[20]
|
R. J. Robert, “Sunitinib: A VEGF and PDGF Receptor Protein Kinase and Angiogenesis Inhibitor,” Biochemical and Biophysical Research Communications, Vol. 356, No. 2, 2007, pp. 323-328. doi:10.1016/j.bbrc.2007.02.156
|
[21]
|
D. Nathalie, S. Carl, N. Sonia and C. Serge, “Human B Lymphocytes and Non-Hodgkin’s Lymphoma Cells Become Polyploid in Response to the Protein Kinase Inhibitor SU6656,” Blood Cells, Molecules, and Diseases, Vol. 39, No. 1, 2007, pp. 130-134.
doi:10.1016/j.bcmd.2007.02.010
|
[22]
|
J. M. Deborah, R. B. Cornelia, C. B. David, U. Ping, H. J. J. Terence, H. K. Sung and G. R. Audie, “SU9516: Biochemical Analysis of cdk Inhibition and Crystal Structure in Complex with cdk2,” Biochemical and Biophysical Research Communications, Vol. 310, No. 3, 2003, pp. 1026-1031. doi:10.1016/j.bbrc.2003.09.114
|
[23]
|
M. E. Lane, B. Yu, A. Rice, K. E. Lipson, C. Liang, L. Sun, C. Tang, G. McMahon, R. G. Pestell and S. Wadler, “A Novel cdk2-Selective Inhibitor, SU9516, Induces Apoptosis in Colon Carcinoma Cells,” Cancer Research, Vol. 61, No. 16, 2001, pp. 6170-6177.
|
[24]
|
M. Yongsheng, C. Eric, W. Xiaomei, S. Chang, M. M. Gerald and B. J. Longley, “Indolinone Derivative Inhibit Constitutively Activated KIT Mutants and Kill Neoplastic Mast Cells,” Journal of Investigative Dermatology, Vol. 114, 2000, pp. 392-394.
doi:10.1046/j.1523-1747.2000.00888.x
|
[25]
|
M. Mohammadi, G. McMahon, L. Sun, C. Tang, P. Hirth, B. K. Yeh, S. R. Hubbard and J. Schlessinger, “Structures of the Tyrosine Kinase Domain of Fibroblast Growth Factor Receptor in Complex with Inhibitors,” Science, Vol. 276, No. 5314, 1997, pp. 955-960.
doi:10.1126/science.276.5314.955
|